For investors who watched the rapid rise and sudden collapse of synthetic biology pioneer Amyris, Inc., the burning question remains: What is the current status of Amyris stock? Whether you are a former shareholder looking to write off your losses on your taxes, or a biotech investor trying to understand where the company stands today, the answer is definitive.

As of the court-approved reorganization plan that went into effect on May 7, 2024, all existing common stock of Amyris, Inc. (formerly traded under NASDAQ: AMRS and later OTC: AMRSQ) has been officially canceled. Common shareholders received zero recovery, and the stock no longer trades. Today, Amyris operates as a private, B2B-focused entity funded by its former secured lenders.

In this comprehensive guide, we will break down exactly how Amyris stock reached this point, the mechanics of its Chapter 11 bankruptcy, how former shareholders can claim tax losses, the current state of "Amyris 2.0" in 2026, and the critical lessons this biotech crash offers for synthetic biology investing.

The Path to Bankruptcy: Why Did Amyris Stock Crash?

To understand the fate of Amyris stock, one must first examine the grand vision that originally captivated Wall Street. Founded in 2003 by a group of post-doctoral researchers from the University of California, Berkeley, Amyris, Inc. was once heralded as the crown jewel of synthetic biology. Armed with initial funding from the Bill & Melinda Gates Foundation, the company set out to use genetically engineered yeast to produce artemisinin, a crucial antimalarial drug that was previously expensive and difficult to extract from sweet wormwood plants. This initial success proved that Amyris’ proprietary "Lab-to-Market" technology platform could program micro-organisms to ferment sugar into high-value chemical compounds.

With proof of concept established, Amyris went public in September 2010, pricing its IPO at $16 per share. The company initially targeted the biofuels market, aiming to replace petroleum-derived diesel and jet fuel with a yeast-fermented hydrocarbon called farnesene. However, this strategy quickly collided with economic reality. Scaling up biological fermentation to compete with cheap, globally traded crude oil proved to be a financial impossibility. The energy inputs, industrial scaling challenges, and a prolonged collapse in oil prices forced Amyris to abandon biofuels and pivot to high-margin specialty ingredients.

This second chapter focused on clean beauty, fragrances, and health and wellness. Using its precision fermentation platform, Amyris successfully developed sustainable alternatives to scarce natural ingredients. Most notably, they engineered yeast to produce squalane—a highly prized moisturizing agent traditionally sourced from shark livers. The company also developed bio-fermented patchouli fragrance, Reb M sweetener, and other specialty chemicals, selling these ingredients B2B to global giants like Estée Lauder, Givaudan, and DSM.

Despite the brilliance of the science, commercializing B2B ingredients proved to have long sales cycles and thin initial margins. Seeking faster paths to monetization, former CEO John Melo led the company into a third, highly ambitious pivot: launching its own direct-to-consumer (D2C) clean beauty and personal care brands.

Between 2016 and 2022, Amyris aggressively launched or acquired a massive portfolio of consumer brands, including Biossance (skincare built around sugarcane-derived squalane), Pipette (baby-care), JVN Hair (haircare with celebrity Jonathan Van Ness), Rose Inc. (cosmetics fronted by Rosie Huntington-Whiteley), Costa Brazil, and Purecane (sweeteners). While this B2C pivot generated massive top-line revenue growth—driving Amyris stock to multi-year highs during the retail investing boom of 2020 and 2021—it hid a structurally flawed business model.

Launching, marketing, and maintaining multiple consumer beauty brands simultaneously is incredibly expensive. Amyris began burning cash at an unsustainable rate. Customer acquisition costs, celebrity royalty deals, manufacturing inefficiencies, and aggressive marketing campaigns outpaced the revenue these brands generated. Instead of funding this expansion out of operational cash flow, Amyris relied on heavy debt issuance.

By late 2022, the company was trapped in a liquidity death spiral, burdened with over $1.15 billion in funded debt. Efforts to streamline operations, including a 30% workforce reduction and the sale of certain ingredient licenses, were too little, too late. On August 9, 2023, Amyris and eleven of its domestic subsidiaries officially filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware under Case No. 23-11131.

The Chapter 11 Reorganization: The Fate of AMRSQ Shareholders

When a public company files for Chapter 11 bankruptcy, retail shareholders often hold onto their stock, hoping for a restructuring plan that preserves some equity value. In the case of Amyris, the transition of its stock ticker from the NASDAQ (AMRS) to the over-the-counter pink sheets under the ticker AMRSQ triggered a flurry of speculative trading. Penny-stock day traders attempted to ride the volatility, fueled by rumors of a potential buyout or a restructuring that might leave some value for common equity.

However, corporate bankruptcy operates under a strict legal hierarchy known as the Absolute Priority Rule. In any Chapter 11 restructuring, creditors must be paid in full before equity holders receive any recovery. Equity holders occupy the absolute bottom of this totem pole, meaning they only receive a payout if the company's assets are worth more than its total debts—a highly rare occurrence.

In the case of Amyris, the math was brutal. The company entered bankruptcy with $1.15 billion in debt, while its highly-hyped consumer brands were valued in subsequent bankruptcy auctions at less than $30 million in aggregate. The core "Lab-to-Market" precision fermentation technology platform failed to attract any qualifying B2B bids above its established $255.8 million reserve price. It became instantly clear that the company was deeply insolvent; its assets were worth a fraction of its outstanding liabilities.

To keep the company operating during the restructuring process, Amyris secured a $190 million Debtor-in-Possession (DIP) superpriority facility backstopped by Euagore, LLC, an affiliate of Foris Ventures LLC. Foris Ventures is an investment firm controlled by L. John Doerr, the billionaire chairman of venture capital giant Kleiner Perkins and a long-time member of Amyris’ board of directors. As the primary secured lender and DIP provider, Doerr’s Foris Ventures held all the cards.

On February 7, 2024, the bankruptcy court entered an order confirming the Fourth Amended Joint Chapter 11 Plan of Reorganization. The plan was highly unusual because Foris Ventures agreed to waive a substantial portion of the debt it was owed and offered to provide up to $160 million in exit financing, despite anticipating over $115 million in operational losses for the business over the subsequent two years. However, this generosity did not extend to common shareholders.

The reorganization plan officially became effective on May 7, 2024. Section K of the confirmed plan outlined the formal cancellation of all existing securities. Every share of AMRSQ common stock, along with all associated notes, options, and warrants, was legally satisfied, discharged, and canceled.

As a result, existing shares of AMRSQ were wiped out entirely. Former common shareholders received zero recovery and no equity in the reorganized company. 100% of the new common stock in Reorganized Amyris was issued to the secured lenders (principally Foris Ventures). The company was deregistered as a public entity, ending any obligation to file financial disclosures with the SEC. For retail investors, the AMRSQ story ended in a total loss. The stock ceased trading, brokerages began removing the ticker from active portfolios, and the company transitioned into a private entity.

How to Claim Amyris Stock Tax Losses: A Practical Guide

While a total loss on an investment is painful, tax laws allow investors to soften the blow through tax loss harvesting. Because Amyris stock was legally canceled and declared worthless, former shareholders can use this loss to offset other capital gains or write off a portion of their ordinary income.

Under Internal Revenue Code (IRC) Section 165(g), when a security becomes completely worthless during the taxable year, the resulting loss is treated as a loss from the sale or exchange of a capital asset on the last day of that taxable year. Because the official effective date of Amyris’ reorganization plan and subsequent stock cancellation was May 7, 2024, the loss is legally recognized as occurring during the 2024 tax year.

If you were an Amyris shareholder, here is how you should handle this on your taxes:

1. Identify Your Cost Basis and Holding Period

To claim the loss, you must determine your exact cost basis (the total amount you paid to acquire the shares, including commissions) and your holding period.

• Short-Term Capital Loss: If you held the Amyris shares for one year or less before May 7, 2024.
• Long-Term Capital Loss: If you held the shares for more than one year before the cancellation date.

2. Review Your Form 1099-B

Major brokerages (such as Charles Schwab, Fidelity, Robinhood, or Vanguard) typically handle worthless securities by removing the ticker and issuing a transaction on Form 1099-B reflecting a sale price of $0.00. Look for a transaction labeled "Worthless Security," "Expired," or "Liquidated" with a date of May 7, 2024, or later in the year. This form will serve as the official record of your realized loss.

3. File IRS Form 8949 and Schedule D

You must report the worthless security transaction on IRS Form 8949 (Sales and Other Dispositions of Capital Assets). On this form, you will list:

• The description of the property (e.g., "Amyris, Inc. Common Stock" or "AMRSQ").
• The date acquired.
• The date sold/disposed of (use the date the stock was canceled, or December 31, 2024, under the end-of-year worthless security rule).
• Proceeds of $0.00.
• Your cost basis.

The totals from Form 8949 are then transferred to Schedule D (Capital Gains and Losses) of your Form 1040.

4. Understand the Capital Loss Deduction Limits

Capital losses are first used to offset any capital gains you realized during the same tax year (both short-term and long-term). If your capital losses exceed your capital gains, you can use the excess loss to offset up to $3,000 of ordinary income ($1,500 if married filing separately) per tax year.

If your total loss on Amyris stock exceeds this $3,000 limit, the remaining balance does not disappear. It becomes a capital loss carryforward, which you can roll over to future tax years indefinitely, offsetting $3,000 of ordinary income each year and offsetting future capital gains until the loss is fully exhausted.

5. Filing Amended Returns (Form 1040-X)

If you failed to report the worthless Amyris stock loss on your 2024 tax return (which was filed in early 2025), you do not have to lose the tax benefit. The IRS allows you to file an amended return using Form 1040-X within three years from the date you filed your original return, or two years from the date you paid the tax, whichever is later. Given the May 2024 cancellation date, you generally have until April 2028 to file an amendment for the 2024 tax year. Note: Tax laws can be complex, and you should always consult a certified public accountant (CPA) or professional tax advisor to evaluate your specific situation.

Amyris 2.0: Where is the Private Company Today in 2026?

With the public stock wiped out and the old retail-oriented business model dismantled, the reorganized company—frequently referred to by industry insiders as "Amyris 2.0"—has returned to its scientific roots. Stripped of the consumer brands that caused its financial ruin, the company is now a private, streamlined, B2B-focused industrial biotechnology firm.

During the bankruptcy proceedings, the company’s consumer brand portfolio was systematically auctioned off. These sales raised critical cash to pay down secured debts, though they represented a massive destruction of the capital originally used to build them. Biossance was acquired by global digital consumer group THG (The Hut Group) for $20 million; JVN Hair was sold to Windsong Global for approximately $1.25 million; Rose Inc. was sold to clean-beauty investment firm AA Cosmeceuticals for $2.5 million. Pipette and other remaining consumer assets were similarly offloaded to various cosmetic brand incubators and private equity buyers.

By shedding these low-margin, high-cost retail businesses, Amyris 2.0 was able to concentrate entirely on its core competency: the design, scale-up, and commercial manufacturing of bio-fermented ingredients. Under the sole ownership of L. John Doerr's Foris Ventures, the company has operated without the constant pressure of public market quarterly earnings, allowing it to focus on long-term capital projects and manufacturing efficiencies.

Throughout 2025 and moving into early 2026, Amyris 2.0 has made strategic moves to reclaim its position as a global leader in precision fermentation. In mid-2025, the company announced the acquisition of full ownership of its state-of-the-art precision fermentation facility in Barra Bonita, Brazil. Amyris bought out food ingredient giant Ingredion's 31% stake in their RealSweet joint venture, which had been established in 2021 to produce fermentation-derived Reb M (a high-purity stevia sweetener).

This transaction was a game-changer for the private company. It dissolved the joint venture, giving Amyris complete operational control over the Barra Bonita facility—widely regarded as one of the most advanced precision fermentation plants in the world. As part of the agreement, Ingredion retained exclusive rights to utilize Amyris’ fermentation technology to commercialize Reb M, while Amyris gained the flexibility to allocate Barra Bonita's production capacity toward other high-value specialty ingredients, such as squalane, hemisqualane, and custom fragrance molecules.

To support this renewed operational push, Amyris has been investing heavily in expanding the Barra Bonita plant. The company is currently completing construction on its fourth precision fermentation line, which is expected to be fully operational in early 2026. This expansion will significantly increase the facility's production capacity and allow for greater flexibility in switching between different fermented products, positioning Amyris 2.0 to capture growing global demand for sustainable, bio-based ingredients from the cosmetics, food, and pharmaceutical industries.

The Synthetic Biology Landscape: Crucial Lessons for Investors

The spectacular collapse of Amyris, Inc. was a watershed moment for the synthetic biology sector. For years, the promise of engineering living organisms to manufacture everything from plastics to medicines was touted as the "next industrial revolution." Venture capitalists and retail investors poured billions into synbio startups, pushing valuations to astronomical heights. However, the Amyris bankruptcy exposed a fundamental challenge that continues to plague the entire industry: the "scale-up canyon of death."

Synthetic biology involves two distinct phases: lab-scale engineering and commercial-scale manufacturing. Lab-scale engineering involves programming DNA and editing yeast or bacteria genomes in a laboratory. Thanks to advances in CRISPR, automation, and AI, this phase has become relatively cheap and highly efficient. Commercial-scale manufacturing, however, requires cultivating these engineered microbes in massive, multi-story industrial bioreactors (often exceeding 200,000 liters) to produce chemicals at a price point that is competitive with traditional petrochemical or agricultural methods.

As Amyris’ history demonstrated, moving from a laboratory petri dish to a commercial bioreactor is not a simple linear scale-up. It is a highly complex biological and physical engineering problem. Microbes behave differently under the intense heat, pressure, and fluid dynamics of massive industrial tanks. Yields often drop, contamination risks skyrocket, and the utility costs (such as electricity and sugar feedstocks) can quickly make the final product economically unviable.

To understand how this impact reverberated across the market, one only needs to look at Amyris’ peers:

• Ginkgo Bioworks (NYSE: DNA): Unlike Amyris, Ginkgo chose a pure-play "foundry" model, focusing on programming cells for third-party customers rather than building its own physical manufacturing plants. Yet, Ginkgo has also struggled to generate consistent, high-margin commercial revenues, and its stock has experienced severe declines from its post-SPAC highs as the market demanded a clear path to profitability over speculative platform growth.
• Zymergen: Once a major competitor in the synbio space, Zymergen went public in a massive 2021 IPO. Just months later, the company admitted that its core optical film product was technically flawed and scaling it was unfeasible. Zymergen’s stock collapsed, and the company was ultimately acquired by Ginkgo Bioworks in 2022 for pennies on the dollar to prevent outright liquidation.

For investors looking at the synthetic biology landscape today, the critical lesson of Amyris stock is that scientific breakthrough does not equal economic viability. Investors must scrutinize a company’s capital expenditure (CapEx) requirements, feedstock supply chains, and path to scale. Furthermore, Amyris proved that attempting to vertically integrate a B2B biotech platform down to a D2C retail consumer brand is a highly risky endeavor. Deep biochemistry and consumer marketing require fundamentally different corporate DNAs; trying to build both simultaneously on a foundation of high-interest debt is an almost guaranteed recipe for financial distress.

FAQs About Amyris Stock (AMRSQ)

Can I still buy or sell Amyris stock (AMRSQ)?

No. As of May 7, 2024, the effective date of the company's Chapter 11 reorganization plan, all existing common shares of Amyris, Inc. were officially canceled and dissolved. The stock no longer trades on the NASDAQ, the OTC market, or any other public exchange. It is legally worthless.

Is there a new public stock ticker for Reorganized Amyris?

No. Amyris 2.0 is a privately held corporation. It is entirely owned by its former secured lenders, primarily Foris Ventures LLC (affiliated with L. John Doerr). There is no public stock ticker, and there are currently no plans for the company to conduct a new initial public offering (IPO).

Did former shareholders receive any payout or stock in the reorganized company?

No. Under the absolute priority rule of U.S. bankruptcy law, common shareholders are the last to receive any distribution of assets. Because Amyris' liabilities far exceeded the value of its assets, secured creditors and DIP lenders took 100% of the equity in the reorganized company. Common stockholders received zero recovery.

What happened to the consumer brands like Biossance and JVN Hair?

During the Chapter 11 bankruptcy process, Amyris auctioned off its consumer brands to different buyers to raise capital. Biossance was sold to THG (The Hut Group), JVN Hair was sold to Windsong Global, and Rose Inc. was acquired by AA Cosmeceuticals. These brands continue to operate under their new ownership, completely independent of Amyris.

How do I write off my AMRS or AMRSQ stock losses on my taxes?

Because the stock was officially canceled and became worthless in 2024, you can claim the loss on your 2024 federal income tax return (filed in 2025). You will need to report the transaction on IRS Form 8949 and Schedule D, using a proceeds value of $0.00. If you missed this deadline, you can file an amended return using Form 1040-X within three years of your original filing date (typically until April 2028).

Are there any ongoing class-action lawsuits that could recover money for shareholders?

While some retail shareholders attempted to organize during the bankruptcy proceedings, the final court-approved reorganization plan included non-consensual third-party releases, which legally protect the restructured company and its key stakeholders from future claims. While individual law firms occasionally investigate potential securities fraud claims related to prepetition management decisions, the likelihood of retail shareholders recovering any meaningful capital through litigation is extremely low.

Conclusion

The story of Amyris stock is a cautionary tale of scientific brilliance undermined by aggressive, debt-fueled overexpansion. The company’s pioneering "Lab-to-Market" synthetic biology platform successfully proved that engineered microbes could manufacture sustainable alternatives to rare chemicals. However, the decision to launch an expensive portfolio of consumer cosmetics brands, funded by over a billion dollars in high-interest debt, created a cash burn that ultimately wiped out the company’s equity.

For former shareholders, the focus now shifts to claiming the capital losses on their tax returns to offset other capital gains and ordinary income. For the broader investment community, Amyris serves as a permanent case study in the capital-intensive reality of scaling deep-tech biochemistry. While "Amyris 2.0" continues to operate privately as a B2B precision fermentation powerhouse in 2026, its public stock has entered the history books as a stark reminder of the risks of investing in pre-profit, high-debt scientific frontiers.